Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY26 results Revenue from Operations: Rs 1,169 million compared to Rs 1,055 million during Q1FY25, change 11%. EBIDTA: Rs 173 million compared to Rs 126 million during Q1FY25, change 37%. EBIDTA Margin: 14.8% for Q1FY26. PAT: Rs 67 million compared to Rs 52 million during Q1FY25, change 28%. PAT Margin: 5.7% for Q1FY26. EPS: Rs 2.84 for Q1FY26. Result PDF
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY25 results Revenue from Operations: Rs 859 million in Q3FY25 (+2% YoY). Total Income: Rs 859 million in Q3FY25 (+1% YoY). EBITDA (Excl. Other Income): Rs 71 million in Q3FY25 (-36% YoY). EBITDA Margin: 8.2% in Q3FY25 (vs. 13.1% in Q3FY24). Profit Before Tax (PBT): Rs (2) million in Q3FY25 (vs. Rs 52 million in Q3FY24). Profit After Tax (PAT): Rs 1 million in Q3FY25 (-96% YoY). PAT Margin: 0.2% in Q3FY25 (vs. 4.1% in Q3FY24). Chairman & MD Chintan Shah Commented: "We endeavor to grow organically by incorporating innovative ideas in our operations, product development and increasing our market presence across product categories" During Q3FY25, the company reported revenue from operations of Rs 859 million, 2% YoY increase. EBITDA during the quarter was at Rs 71 million, 36% YoY decline. EBIDTA margins were at 8.2% v/s 13.1% in Q3FY24. During 9MFY25, the company reported revenue from operations of Rs 2,749 million, 7% YoY decline. EBITDA during same period was at Rs 256 million, 51% YoY decline. EBIDTA margins were at 9.3% v/s 17.8% in 9MFY25. As we step into this promising new year 2025, we at TATVA CHINTAN are confident to finally reap the rewards of the hard work, persistence, and resilience that have defined our efforts over the past few quarters. Overall, the market situation continues to remain subdued in terms of demand but we are beginning to see a faint sense of improvement in the market. Industry as a whole seems to have begun the path to recovery. While we may not have completely left the challenges of the past behind, there are encouraging signs pointing toward better business prospects over the coming quarters. Raw material prices have shown relative stability, and sea freight rates have moderated. We are pleased to inform that we have successfully started distillation plant in January 2025. This new facility will significantly ease production capacities to manufacture some of our major products Our focus is on development of products for use in semiconductor and electronics industry which will become our growth engine after three years. We have made significant headway in coming close to the ultra-high purity quality requirements. In these turbulent times, the strength that has kept us resilient and afloat has been our unwavering R&D; capabilities. Our vision for the future is deeply embedded in the projects we undertake in R&D;, which boasts a robust pipeline of high-value products with immense business potential. Result PDF
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Tatva Chintan Pharma Chem announced H1FY25 & Q2FY25 results During Q2FY25, the company reported revenue from operations of Rs 835 million, decline by 14% YoY. EBITDA during the quarter was at Rs 56 million, decline by 72% YoY. EBIDTA margins were at 6.7% v/s 20.9% in Q2FY24. During H1FY25, the company reported revenue from operations of Rs 1,890 million, decline by 10% YoY. EBITDA during same period was at Rs 182 million, decline by 56% YoY. EBIDTA margins were at 9.6% v/s 19.7% in H1FY24. Chintan Shah, CMD, Tatva Chintan Pharma Chem, said: "We continue to grow organically by incorporating innovative ideas across operations and increasing our product portfolio across product categories. The specialty chemical industry continues to face challenges across major end-user sectors. These challenges are arising largely from weaker global demand and increased competition from Chinese suppliers. Owing to geopolitical issues the long transit times is also hurting the industry. Among these challenges we also see some positives like ongoing reduction in freight rates, destocking by the customers is nearly ending and bottoming of key raw material prices. We foresee the trend of weaker demand will continue through Q3 as customers are cautious about the inventory levels towards the end of their financial year. We anticipate gradual uptick in demand from Q4 and global demands will improve over the coming quarters. We have a robust pipeline of products across various stages like R&D;, pilot level, plant scale, and those under approval or recently approved. These products are poised to generate additional revenue beyond the company’s current turnover. Despite the current challenges, I continue to remain genuinely optimistic. We have multiple products under commercialisation which will lead to a strong growth. At TATVA CHINTAN, we are confident in our ability to navigate these tough times with resilience, while continuing to nurture and strengthen our relationships with existing customers and also bringing in new products and new customers onboard." Result PDF